pharmaceutical preparations

Summary

Summary: Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form.

Top Publications

  1. ncbi DrugBank: a knowledgebase for drugs, drug actions and drug targets
    David S Wishart
    Department of Computing Science, University of Alberta, Edmonton, AB, Canada T6G 2E8
    Nucleic Acids Res 36:D901-6. 2008
  2. ncbi Predicting new molecular targets for known drugs
    Michael J Keiser
    Department of Pharmaceutical Chemistry, University of California San Francisco, 1700 4th Street, San Francisco, California 94143 2550, USA
    Nature 462:175-81. 2009
  3. ncbi PubChem: a public information system for analyzing bioactivities of small molecules
    Yanli Wang
    National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD 20894, USA
    Nucleic Acids Res 37:W623-33. 2009
  4. ncbi Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
    C A Lipinski
    Central Research Division, Pfizer Inc, Groton, CT 06340, USA
    Adv Drug Deliv Rev 46:3-26. 2001
  5. ncbi STITCH 2: an interaction network database for small molecules and proteins
    Michael Kuhn
    Biotechnology Center, TU Dresden, 01062 Dresden, Germany
    Nucleic Acids Res 38:D552-6. 2010
  6. ncbi Drug target identification using side-effect similarity
    Monica Campillos
    European Molecular Biology Laboratory EMBL, Meyerhofstrasse 1, 69117 Heidelberg, Germany
    Science 321:263-6. 2008
  7. ncbi Benchmarking sets for molecular docking
    Niu Huang
    Department of Pharmaceutical Chemistry, University of California San Francisco, QB3 Building, 1700 4th Street, Box 2550, San Francisco, California 94143-2550, USA
    J Med Chem 49:6789-801. 2006
  8. ncbi Update of TTD: Therapeutic Target Database
    Feng Zhu
    Department of Pharmacy and Computation and Systems Biology, Center for Computational Science and Engineering, Singapore MIT Alliance, National University of Singapore, Singapore
    Nucleic Acids Res 38:D787-91. 2010
  9. ncbi ADMET in silico modelling: towards prediction paradise?
    Han van de Waterbeemd
    Pfizer Global Research and Development, PDM, Sandwich, Kent CT13 9NJ, UK
    Nat Rev Drug Discov 2:192-204. 2003
  10. ncbi Global mapping of pharmacological space
    Gaia V Paolini
    The Department of Knowledge Discovery, Pfizer Global Research and Development, Sandwich, Kent CT13 9NJ, UK
    Nat Biotechnol 24:805-15. 2006

Research Grants

  1. Mechanisms of Manganese Neurotoxicity
    ANUMANTHA GOUNDER KANTHASAMY; Fiscal Year: 2010
  2. Mechanisms of Manganese Neurotoxicity
    ANUMANTHA GOUNDER KANTHASAMY; Fiscal Year: 2010
  3. TARGETED METAL CHELATORS FOR DIAGNOSTIC IMAGING
    Michael Welch; Fiscal Year: 2001
  4. TARGETED METAL CHELATORS FOR DIAGNOSTIC IMAGING
    Michael Welch; Fiscal Year: 1993
  5. Bi(III)-Initiated Chemistry: Mechanistic Investigations of Catalytic Activity
    Robert Hinkle; Fiscal Year: 2007
  6. Label Free Pharmaceutical Anticounterfeiting Technology
    ROBERT HAUSHALTER; Fiscal Year: 2007
  7. CONTROLLED RELEASE OF MACROMOLECULES
    Robert Langer; Fiscal Year: 2003
  8. Pharmaceutical Anticounterfeiting Technology
    ROBERT HAUSHALTER; Fiscal Year: 2005
  9. ACYL GLUCURONIDES: COVALENT BINDING & PHARMACOKINETICS
    Leslie Benet; Fiscal Year: 1993
  10. Metabolism of Carcinogens and Drugs by Human P450s
    F Guengerich; Fiscal Year: 2007

Detail Information

Publications250 found, 100 shown here

  1. ncbi DrugBank: a knowledgebase for drugs, drug actions and drug targets
    David S Wishart
    Department of Computing Science, University of Alberta, Edmonton, AB, Canada T6G 2E8
    Nucleic Acids Res 36:D901-6. 2008
    ..DrugBank has also significantly improved the power and simplicity of its structure query and text query searches. DrugBank is available at http://www.drugbank.ca...
  2. ncbi Predicting new molecular targets for known drugs
    Michael J Keiser
    Department of Pharmaceutical Chemistry, University of California San Francisco, 1700 4th Street, San Francisco, California 94143 2550, USA
    Nature 462:175-81. 2009
    ..The chemical similarity approach is systematic and comprehensive, and may suggest side-effects and new indications for many drugs...
  3. ncbi PubChem: a public information system for analyzing bioactivities of small molecules
    Yanli Wang
    National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD 20894, USA
    Nucleic Acids Res 37:W623-33. 2009
    ..Most of the tools described in this work can be directly accessed at http://pubchem.ncbi.nlm.nih.gov/assay/. URLs for accessing other tools described in this work are specified individually...
  4. ncbi Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
    C A Lipinski
    Central Research Division, Pfizer Inc, Groton, CT 06340, USA
    Adv Drug Deliv Rev 46:3-26. 2001
    ..Recent work on linear free energy relationships and Log P approaches are critically reviewed. Useful predictions are possible in closely related analog series when coupled with experimental thermodynamic solubility measurements...
  5. ncbi STITCH 2: an interaction network database for small molecules and proteins
    Michael Kuhn
    Biotechnology Center, TU Dresden, 01062 Dresden, Germany
    Nucleic Acids Res 38:D552-6. 2010
    ..STITCH 2.0 connects proteins from 630 organisms to over 74,000 different chemicals, including 2200 drugs. STITCH can be accessed at http://stitch.embl.de/...
  6. ncbi Drug target identification using side-effect similarity
    Monica Campillos
    European Molecular Biology Laboratory EMBL, Meyerhofstrasse 1, 69117 Heidelberg, Germany
    Science 321:263-6. 2008
    ..Nine of these were tested and confirmed in cell assays, documenting the feasibility of using phenotypic information to infer molecular interactions and hinting at new uses of marketed drugs...
  7. ncbi Benchmarking sets for molecular docking
    Niu Huang
    Department of Pharmaceutical Chemistry, University of California San Francisco, QB3 Building, 1700 4th Street, Box 2550, San Francisco, California 94143-2550, USA
    J Med Chem 49:6789-801. 2006
    ..DUD is freely available online as a benchmarking set for docking at http://blaster.docking.org/dud/...
  8. ncbi Update of TTD: Therapeutic Target Database
    Feng Zhu
    Department of Pharmacy and Computation and Systems Biology, Center for Computational Science and Engineering, Singapore MIT Alliance, National University of Singapore, Singapore
    Nucleic Acids Res 38:D787-91. 2010
    ..This database can be accessed at http://bidd.nus.edu.sg/group/cjttd/TTD.asp...
  9. ncbi ADMET in silico modelling: towards prediction paradise?
    Han van de Waterbeemd
    Pfizer Global Research and Development, PDM, Sandwich, Kent CT13 9NJ, UK
    Nat Rev Drug Discov 2:192-204. 2003
    ..Here, we describe how in silico approaches will further increase our ability to predict and model the most relevant pharmacokinetic, metabolic and toxicity endpoints, thereby accelerating the drug discovery process...
  10. ncbi Global mapping of pharmacological space
    Gaia V Paolini
    The Department of Knowledge Discovery, Pfizer Global Research and Development, Sandwich, Kent CT13 9NJ, UK
    Nat Biotechnol 24:805-15. 2006
    ..The relationships between proteins, chemical structures and drug-like properties provide a framework for developing a probabilistic approach to drug discovery that can be exploited to increase research productivity...
  11. ncbi Recent developments of the chemistry development kit (CDK) - an open-source java library for chemo- and bioinformatics
    Christoph Steinbeck
    Cologne University Bioinformatics Center CUBIC, Germany
    Curr Pharm Des 12:2111-20. 2006
    ..This article introduces the CDK's new QSAR capabilities and the recently introduced interface to statistical software...
  12. ncbi SuperTarget and Matador: resources for exploring drug-target relationships
    Stefan Günther
    Structural Bioinformatics Group, Institute of Molecular Biology and Bioinformatics, Charite University Medicine Berlin, Arnimallee 22, 14195 Berlin, Germany
    Nucleic Acids Res 36:D919-22. 2008
    ..SuperTarget and Matador are available at http://insilico.charite.de/supertarget and http://matador.embl.de...
  13. ncbi Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework
    Yoshihiro Yamanishi
    Mines ParisTech, Centre for Computational Biology, 35 rue Saint Honore, F 77305 Fontainebleau Cedex, Institut Curie, F 75248, INSERM U900, F 75248, Paris, France
    Bioinformatics 26:i246-54. 2010
    ..There is therefore a strong incentive to develop new methods capable of detecting these potential drug-target interactions efficiently...
  14. ncbi A side effect resource to capture phenotypic effects of drugs
    Michael Kuhn
    Structural and Computational Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany
    Mol Syst Biol 6:343. 2010
    ..We illustrate the potential of SIDER with a number of analyses. The resource is freely available for academic research at http://sideeffects.embl.de...
  15. ncbi KEGG for linking genomes to life and the environment
    Minoru Kanehisa
    Bioinformatics Center, Institute for Chemical Research, Kyoto University, Uji, Kyoto, Japan
    Nucleic Acids Res 36:D480-4. 2008
    ..KEGG DRUG contains all approved drugs in the US and Japan, and KEGG DISEASE is a new database linking disease genes, pathways, drugs and diagnostic markers...
  16. ncbi Systematic evaluation of drug-disease relationships to identify leads for novel drug uses
    A P Chiang
    Department of Medicine, Stanford Center for Biomedical Informatics Research, Stanford University, Stanford, California, USA
    Clin Pharmacol Ther 86:507-10. 2009
    ..When compared with a control group of drug uses, the suggested novel drug uses generated by this approach were significantly enriched with respect to previous and ongoing clinical trials...
  17. ncbi Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast
    Ainslie B Parsons
    Banting and Best Department of Medical Research, University of Toronto, Toronto, Ontario M5G 1L6, Canada
    Cell 126:611-25. 2006
    ..This compendium should serve as a valuable key for interpreting cellular effects of novel compounds with similar activities...
  18. ncbi Identifying the proteins to which small-molecule probes and drugs bind in cells
    Shao En Ong
    Proteomics Platform, The Broad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA 02142, USA
    Proc Natl Acad Sci U S A 106:4617-22. 2009
    ..Here, we describe in full detail the application of the method to identify targets of kinase inhibitors and immunophilin binders...
  19. ncbi Virtual screening of chemical libraries
    Brian K Shoichet
    Department of Pharmaceutical Chemistry, University of California, 600 16th Street, San Francisco, California 94143 2240, USA
    Nature 432:862-5. 2004
    ....
  20. ncbi DrugBank: a comprehensive resource for in silico drug discovery and exploration
    David S Wishart
    Department of Computing Science, University of Alberta, Edmonton, AB, Canada T6G 2E8
    Nucleic Acids Res 34:D668-72. 2006
    ..DrugBank is available at http://redpoll.pharmacy.ualberta.ca/drugbank/...
  21. ncbi Relating protein pharmacology by ligand chemistry
    Michael J Keiser
    Department of Pharmaceutical Chemistry, University of California San Francisco, 1700 4th St, San Francisco California 94143 2550, USA
    Nat Biotechnol 25:197-206. 2007
    ..These predictions were subsequently confirmed experimentally. Relating receptors by ligand chemistry organizes biology to reveal unexpected relationships that may be assayed using the ligands themselves...
  22. ncbi The many roles of computation in drug discovery
    William L Jorgensen
    Department of Chemistry, Yale University, New Haven, CT 06520 8107, USA
    Science 303:1813-8. 2004
    ..Particular emphasis is placed on virtual screening, de novo design, evaluation of drug-likeness, and advanced methods for determining protein-ligand binding...
  23. ncbi Medication errors and adverse drug events in pediatric inpatients
    R Kaushal
    Children's Hospital, Enders 609, Longwood Avenue, Boston, MA 02115, USA
    JAMA 285:2114-20. 2001
    ..CONCLUSIONS: Medication errors are common in pediatric inpatient settings, and further efforts are needed to reduce them...
  24. ncbi Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999-2000: a national reconnaissance
    Dana W Kolpin
    US Geological Survey, Iowa City, Iowa 52244, USA
    Environ Sci Technol 36:1202-11. 2002
    ....
  25. ncbi A robustness-based approach to systems-oriented drug design
    Hiroaki Kitano
    Sony Computer Science Laboratories Inc, 3 14 13 Higashi Gotanda, Shinagawa, Tokyo 141 0022, Japan
    Nat Rev Drug Discov 6:202-10. 2007
    ....
  26. ncbi 'Metabolite-likeness' as a criterion in the design and selection of pharmaceutical drug libraries
    Paul D Dobson
    School of Chemistry and The Manchester Interdisciplinary Biocentre, The University of Manchester, 131 Princess St, Manchester M1 7DN, UK
    Drug Discov Today 14:31-40. 2009
    ....
  27. ncbi Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties
    P Ertl
    Cheminformatics, Novartis Pharma AG, WKL 490 4 35, CH 4002 Basel, Switzerland
    J Med Chem 43:3714-7. 2000
    ..This article describes the new methodology and shows the results of validation studies based on sets of published absorption data, including intestinal absorption, Caco-2 monolayer penetration, and blood-brain barrier penetration...
  28. ncbi From genomics to chemical genomics: new developments in KEGG
    Minoru Kanehisa
    Bioinformatics Center, Institute for Chemical Research, Kyoto University, Uji, Kyoto 611 0011, Japan
    Nucleic Acids Res 34:D354-7. 2006
    ..Additionally, drug information is now stored separately and linked to new KEGG DRUG structure maps...
  29. ncbi Drug-related problems in hospitals: a review of the recent literature
    Anita Krähenbühl Melcher
    Hospital Pharmacy, Regionalspital Emmental, Burgdorf, Switzerland
    Drug Saf 30:379-407. 2007
    ....
  30. ncbi STITCH: interaction networks of chemicals and proteins
    Michael Kuhn
    European Molecular Biology Laboratory, Meyerhofstrasse 1, 69117 Heidelberg, Germany
    Nucleic Acids Res 36:D684-8. 2008
    ..5 million genes across 373 genomes and their interactions contained in the STRING database. STITCH is available at http://stitch.embl.de/...
  31. ncbi Comparison of support vector machine and artificial neural network systems for drug/nondrug classification
    Evgeny Byvatov
    , , Marie-Curie-Strasse 11, D-60439 Frankfurt, Germany
    J Chem Inf Comput Sci 43:1882-9. 2003
    ..The theory of SVM and ANN training is briefly reviewed...
  32. ncbi ChEBI: a database and ontology for chemical entities of biological interest
    Kirill Degtyarenko
    European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK
    Nucleic Acids Res 36:D344-50. 2008
    ..ChEBI includes an ontological classification, whereby the relationships between molecular entities or classes of entities and their parents and/or children are specified. ChEBI is available online at http://www.ebi.ac.uk/chebi/..
  33. ncbi Extracting medication information from clinical text
    Ozlem Uzuner
    Department of Information Studies, University at Albany, State University of New York, Albany, NY, USA
    J Am Med Inform Assoc 17:514-8. 2010
    ..However, they are limited in recognizing duration and reason fields and would benefit from future research...
  34. ncbi Supervised prediction of drug-target interactions using bipartite local models
    Kevin Bleakley
    Mines ParisTech, Centre for Computational Biology, Fontainebleau, France
    Bioinformatics 25:2397-403. 2009
    ..This, however, remains extremely challenging due to, amongst other things, the rarity of known drug-target interactions...
  35. ncbi Stability of protein pharmaceuticals: an update
    Mark Cornell Manning
    Legacy BioDesign LLC, Johnstown, Colorado 80534, USA
    Pharm Res 27:544-75. 2010
    ....
  36. ncbi The chemical basis of pharmacology
    Michael J Keiser
    Department of Pharmaceutical Chemistry, University of California San Francisco, 1700 4th Street, San Francisco, CA 94158 2558, USA
    Biochemistry 49:10267-76. 2010
    ..The bases for these new methods, some of their successes and liabilities, and new opportunities for their use are described...
  37. ncbi Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system
    Chi-Yuan Wu
    Department of Biopharmaceutical Sciences, University of California San Francisco, San Francisco, California 94143, USA
    Pharm Res 22:11-23. 2005
    ....
  38. ncbi Building disease-specific drug-protein connectivity maps from molecular interaction networks and PubMed abstracts
    Jiao Li
    State Key Laboratory of Intelligent Technology and Systems, Tsinghua National Laboratory for Information Science and Technology, Department of Computer Science and Technology, Tsinghua University, Beijing, China
    PLoS Comput Biol 5:e1000450. 2009
    ....
  39. ncbi Graphic rule for drug metabolism systems
    Kuo Chen Chou
    Gordon Life Science Institute, 13784 Torrey Del Mar Drive, San Diego, CA 92130, USA
    Curr Drug Metab 11:369-78. 2010
    ..g., according to their directed graphs, the metabolism of seliciclib and the metabolism of vildagliptin can be categorized as 0-->5 mechanism while that of AG-024322 as 0-->4-->3 mechanism...
  40. ncbi Searching for safety: addressing search engine, website, and provider accountability for illicit online drug sales
    Bryan A Liang
    Institute of Health Law Studies, California Western School of Law, San Diego, CA, USA
    Am J Law Med 35:125-84. 2009
    ....
  41. ncbi Micellar solubilization of drugs
    Carlota Oliveira Rangel-Yagui
    Department of Biochemical and Pharmaceutical Technology FCF, University of Sao Paulo, Sao Paulo, Brazil
    J Pharm Pharm Sci 8:147-65. 2005
    ..Micellar solubilization is a powerful alternative for dissolving hydrophobic drugs in aqueous environments. In this work, we provide an insight into this subject...
  42. ncbi Chemiluminescence detection in liquid chromatography: applications to clinical, pharmaceutical, environmental and food analysis--a review
    Laura Gámiz-Gracia
    Department of Analytical Chemistry, Faculty of Sciences, Campus Fuentenueva, University of Granada, E 18071 Granada, Spain
    Anal Chim Acta 640:7-28. 2009
    ..The review covers the literature from 2000 until the end of 2008...
  43. ncbi An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery
    Neil Parrott
    F Hoffmann La Roche AG, Pharmaceuticals Division, CH 4070 Bl, Switzerland
    J Pharm Sci 94:2327-43. 2005
    ..However verification of the simulations with in vivo data for a few compounds of each compound class is recommended since recent discovery compounds may have properties beyond the scope of the current generic models...
  44. ncbi Modelling and PBPK simulation in drug discovery
    Hannah M Jones
    Pfizer Global R and D, Department of Pharmacokinetics, Dynamics and Metabolism, IPC 654, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK
    AAPS J 11:155-66. 2009
    ....
  45. ncbi Sex differences in pharmacokinetics and pharmacodynamics
    Offie P Soldin
    Departments of Medicine, Oncology and Physiology, Center for the Study of Sex Differences, Georgetown University Medical Center, Washington, DC, USA
    Clin Pharmacokinet 48:143-57. 2009
    ..Since this is a rapidly evolving area, it is essential for the practitioner to review drug prescribing information and recent literature in order to fully understand the impact of these differences on clinical therapeutics...
  46. ncbi Drug effects viewed from a signal transduction network perspective
    Anton F Fliri
    Pfizer Global Research and Development, CT, USA
    J Med Chem 52:8038-46. 2009
    ..These protein network topology models reveal that drugs having similar pharmacology profiles reach similar discrete positions in cellular protein network systems and provide a network view of medicine cause-effect relationships...
  47. ncbi Observational study of potential risk factors of medication administration errors
    Edgar Tissot
    Pharmacy Department, , Boulevard Fleming, , France
    Pharm World Sci 25:264-8. 2003
    ..CONCLUSION: According to these data, the quality of the medication administration process needs to be optimized in hospitals in order to minimize the incidence of iatrogenic preventable diseases...
  48. ncbi Physiologically-based pharmacokinetic simulation modelling
    George M Grass
    LION Bioscience, 9880 Campus Point Drive, San Diego, CA 92121, USA
    Adv Drug Deliv Rev 54:433-51. 2002
    ....
  49. ncbi Data-driven methods to discover molecular determinants of serious adverse drug events
    A P Chiang
    Department of Medicine, Stanford Center for Biomedical Informatics, Stanford University School of Medicine, Stanford, California, USA
    Clin Pharmacol Ther 85:259-68. 2009
    ..We also describe recent examples of how bioinformatics methods coupled with data repositories can advance the science of SADRs...
  50. ncbi Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs
    J Kelder
    Department of Molecular Design and Informatics, NV Organon, Oss, The Netherlands
    Pharm Res 16:1514-9. 1999
    ..To study oral absorption and brain penetration as a function of polar molecular surface area...
  51. ncbi A topological substructural approach for the prediction of P-glycoprotein substrates
    Miguel Angel Cabrera
    Department of Drug Design, Centre of Chemical Bioactive, Central University of Las Villas, Santa Clara, Villa Clara, Cuba
    J Pharm Sci 95:589-606. 2006
    ....
  52. ncbi Mathematical modeling of drug delivery
    J Siepmann
    College of Pharmacy, JE 2491, University of Lille, 3 rue du Professeur Laguesse, 59006 Lille, France
    Int J Pharm 364:328-43. 2008
    ..Ideally, the effects of the design parameters of the dosage form on the resulting drug concentration time profiles at the site of action and the pharmacodynamic effects will become predictable...
  53. ncbi SMPDB: The Small Molecule Pathway Database
    Alex Frolkis
    Department of Computing Science, University of Alberta, Edmonton, AB, Canada
    Nucleic Acids Res 38:D480-7. 2010
    ..Gene, metabolite and protein concentration data can also be visualized through SMPDB's mapping interface. All of SMPDB's images, image maps, descriptions and tables are downloadable. SMPDB is available at: http://www.smpdb.ca...
  54. ncbi Computation of octanol-water partition coefficients by guiding an additive model with knowledge
    Tiejun Cheng
    State Key Laboratory of Bioorganic Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 354 Fenglin Road, Shanghai, P R China
    J Chem Inf Model 47:2140-8. 2007
    ..It is also able to utilize the ever-increasing experimentally measured logP data more effectively...
  55. ncbi Timing of new black box warnings and withdrawals for prescription medications
    Karen E Lasser
    Department of Medicine, Cambridge Hospital, Cambridge, MA 02139, USA
    JAMA 287:2215-20. 2002
    ..Recently approved drugs may be more likely to have unrecognized adverse drug reactions (ADRs) than established drugs, but no recent studies have examined how frequently postmarketing surveillance identifies important ADRs...
  56. ncbi Structure-based virtual screening: an overview
    Paul D Lyne
    AstraZeneca R and D Boston, Waltham, MA 02451, USA
    Drug Discov Today 7:1047-55. 2002
    ..Here, the current strengths and weaknesses of the technology are discussed, and emphasis is placed on aspects of the work-flow of a virtual screening campaign, from preparation through to post-screening analysis...
  57. ncbi Large-scale prediction of drug-target relationships
    Michael Kuhn
    European Molecular Biology Laboratory, Meyerhofstrasse 1, 69117 Heidelberg, Germany
    FEBS Lett 582:1283-90. 2008
    ..We finally discuss how phenotypic data could help to expand our understanding of the complex mechanisms of drug action...
  58. ncbi Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4
    Shu Feng Zhou
    Division of Chinese Medicine, School of Health Sciences, WHO Collaborating Center for Traditional Medicine, RMIT University, Victoria, Australia
    Curr Drug Metab 9:310-22. 2008
    ....
  59. ncbi Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies
    Nicola J Hewitt
    Scientific Writing Services, Wingertstrasse, Erzhausen, Germany
    Drug Metab Rev 39:159-234. 2007
    ..We also report pharmaceutical perspectives of these topics and compare methods and interpretations for the drug development process...
  60. ncbi SuperToxic: a comprehensive database of toxic compounds
    Ulrike Schmidt
    Structural Bioinformatics Group, Institute of Molecular Biology and Bioinformatics, Charite University Medicine Berlin, Arnimallee 22, 14195 Berlin, Germany
    Nucleic Acids Res 37:D295-9. 2009
    ..This database is available online at: http://bioinformatics.charite.de/supertoxic...
  61. ncbi Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs
    Kelly M Mahar Doan
    Preclinical Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    J Pharmacol Exp Ther 303:1029-37. 2002
    ..For CNS delivery, a drug should ideally have an in vitro passive permeability >150 nm/s and not be a good (B --> A/A --> B ratio <2.5) Pgp substrate...
  62. ncbi Overriding of drug safety alerts in computerized physician order entry
    Heleen van der Sijs
    Department of Hospital Pharmacy, Erasmus University Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    J Am Med Inform Assoc 13:138-47. 2006
    ..Studies on cognitive processes playing a role in overriding drug safety alerts are lacking...
  63. ncbi PROMISCUOUS: a database for network-based drug-repositioning
    Joachim von Eichborn
    Charite Universitatsmedizin Berlin, Institute for Physiology, Structural Bioinformatics Group, Lindenberger Weg 80, 13125 Berlin, Germany
    Nucleic Acids Res 39:D1060-6. 2011
    ..This network-based approach can provide a starting point for drug-repositioning. PROMISCUOUS is publicly available at http://bioinformatics.charite.de/promiscuous...
  64. ncbi Mitochondrial abnormalities--a link to idiosyncratic drug hepatotoxicity?
    Urs A Boelsterli
    Molecular Toxicology Lab, Department of Pharmacology, Yong Loo Lin School of Medicine, Singapore
    Toxicol Appl Pharmacol 220:92-107. 2007
    ..New animal models (e.g., the Sod2(+/-) mouse) provide supporting evidence for this concept. However, genetic analyses of DILI patient samples are needed to ultimately provide the proof-of-concept...
  65. ncbi EDULISS: a small-molecule database with data-mining and pharmacophore searching capabilities
    Kun Yi Hsin
    The Centre for Translational and Chemical Biology, The University of Edinburgh, King s Buildings, Edinburgh, UK
    Nucleic Acids Res 39:D1042-8. 2011
    ..Two ligand searching applications are given to demonstrate how EDULISS can be used to extract families of molecules with selected structural and biophysical features...
  66. ncbi Simulation and prediction of in vivo drug metabolism in human populations from in vitro data
    Amin Rostami-Hodjegan
    Academic Unit of Clinical Pharmacology, Floor M, The Royal Hallamshire Hospital, Sheffield S10 2JF, and Simcyp Ltd, The Blades Enterprise Centre, John Street, Sheffield S2 4SU, UK
    Nat Rev Drug Discov 6:140-8. 2007
    ..An effort to build virtual populations using extensive demographic, physiological, genomic and in vitro biochemical data to simulate and predict drug disposition from routinely collected in vitro data is outlined...
  67. ncbi Computational prediction of human drug metabolism
    Sean Ekins
    GeneGo, Inc, 500 Renaissance Drive, Suite 106, St Joseph, MI 49085, USA
    Expert Opin Drug Metab Toxicol 1:303-24. 2005
    ..This will ultimately aid in hypothesis generation and the early triaging of molecules likely to have undesirable predicted properties or measured effects on key proteins and cellular functions...
  68. ncbi The influence of drug-like concepts on decision-making in medicinal chemistry
    Paul D Leeson
    AstraZeneca R and D Charnwood, Bakewell Road, Loughborough LE15 5RH, UK
    Nat Rev Drug Discov 6:881-90. 2007
    ..Tackling the threat of compound-related toxicological attrition needs to move to the mainstream of medicinal chemistry decision-making...
  69. ncbi The incidence and nature of prescribing and medication administration errors in paediatric inpatients
    Maisoon Abdullah Ghaleb
    Department of Practice and Policy, The School of Pharmacy, University of Hertfordshire, Hatfield AL10 9AB, UK
    Arch Dis Child 95:113-8. 2010
    ..To determine the incidence and nature of prescribing and medication administration errors in paediatric inpatients...
  70. ncbi Prediction of passive blood-brain partitioning: straightforward and effective classification models based on in silico derived physicochemical descriptors
    Santiago Vilar
    Laboratory of Biological Modeling, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, DHHS, Bethesda, MD 20892, USA
    J Mol Graph Model 28:899-903. 2010
    ....
  71. ncbi Consumer reporting of adverse drug reactions: a retrospective analysis of the Danish adverse drug reaction database from 2004 to 2006
    Lise Aagaard
    Department of Pharmacology and Pharmacotherapy, Section for Social Pharmacy, Faculty of Pharmaceutical Sciences, University of Copenhagen, Copenhagen, Denmark
    Drug Saf 32:1067-74. 2009
    ..The objective of this study was to compare ADRs reported by consumers with ADRs reported from other sources, in terms of their type, seriousness and the suspected medicines involved...
  72. ncbi Predicting drug side-effects by chemical systems biology
    Nicholas P Tatonetti
    Training Program in Biomedical Informatics, Stanford University, Stanford, CA 94305, USA
    Genome Biol 10:238. 2009
    ..New approaches to predicting ligand similarity and protein interactions can explain unexpected observations of drug inefficacy or side-effects...
  73. ncbi Utilising atomic force microscopy for the characterisation of nanoscale drug delivery systems
    Johannes Sitterberg
    Department of Pharmaceutical Technology and Biopharmacy, Philipps Universitat Marburg, Marburg, Germany
    Eur J Pharm Biopharm 74:2-13. 2010
    ....
  74. ncbi Harvesting candidate genes responsible for serious adverse drug reactions from a chemical-protein interactome
    Lun Yang
    Bio X Center, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders Ministry of Education, Shanghai Jiao Tong University, Shanghai, China
    PLoS Comput Biol 5:e1000441. 2009
    ..In conclusion, SADR targets and the patient-specific off-targets could be identified through a systematic investigation of the CPI, generating important hypotheses for prospective experimental validation of the candidate genes...
  75. ncbi Detecting drug targets with minimum side effects in metabolic networks
    Z Li
    Beijing Wuzi University, School of Information, Beijing, People s Republic of China
    IET Syst Biol 3:523-33. 2009
    ..The results show that our approach can identify the optimal drug targets in an exact and efficient manner. In particular, it can be applied to large-scale networks including the whole metabolic networks from most organisms...
  76. ncbi SePreSA: a server for the prediction of populations susceptible to serious adverse drug reactions implementing the methodology of a chemical-protein interactome
    Lun Yang
    Bio X Center, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders Ministry of Education, Shanghai Jiao Tong University, Shanghai 200030, PR China
    Nucleic Acids Res 37:W406-12. 2009
    ..The server is freely available at http://SePreSA.Bio-X.cn/...
  77. ncbi Pharmaceutical applications of confocal laser scanning microscopy: the physical characterisation of pharmaceutical systems
    Samuel R Pygall
    Formulation Insights, School of Pharmacy, University of Nottingham, University Park, Nottingham, NG7 2RD, United Kingdom
    Adv Drug Deliv Rev 59:1434-52. 2007
    ..In the future, there is continuing scope for wider exploitation of existing techniques, and continuing advancements in instrumentation...
  78. ncbi The role of drug transporters at the blood-brain barrier
    A G de Boer
    Blood Brain Barrier Research Group, Division of Pharmacology, Leiden Amsterdam Center for Drug Research, University of Leiden, The Netherlands
    Annu Rev Pharmacol Toxicol 43:629-56. 2003
    ....
  79. ncbi Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma
    Hans Georg Eichler
    European Medicines Agency, Canary Wharf, London, UK
    Nat Rev Drug Discov 7:818-26. 2008
    ....
  80. ncbi Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport
    Manthena V S Varma
    Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Sector No. 67, SAS Nagar 160 062, Punjab, India
    Mol Pharm 2:12-21. 2005
    ..Thus, integrating these factors with drug characteristics of the Biopharmaceutics Classification System (BCS) class better predicts the functional role of P-gp in limiting intestinal drug absorption...
  81. ncbi The use of questionnaires for measuring patient-reported side effects of drugs: its importance and methodological challenges
    Juliet M Foster
    Department of General Practice, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    Pharmacoepidemiol Drug Saf 17:278-96. 2008
    ....
  82. ncbi Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis
    M A Perazella
    Department of Medicine, Yale University School of Medicine, New Haven, Conn 06520 8029, USA
    J Gen Intern Med 12:646-56. 1997
    ....
  83. ncbi Liver function and phase I drug metabolism in the elderly: a paradox
    D L Schmucker
    Cell Biology and Aging Section 151E, Veterans Affairs Medical Center, San Francisco, California 94121, USA
    Drugs Aging 18:837-51. 2001
    ....
  84. ncbi Effect of computer order entry on prevention of serious medication errors in hospitalized children
    Kathleen E Walsh
    Department of Pediatrics, University of Massachusetts Medical School UMass Memorial Medical Center, Worcester, Massachusetts 01655, USA
    Pediatrics 121:e421-7. 2008
    ..Our objective was to evaluate comprehensively the effect of computerized physician order entry on the rate of inpatient pediatric medication errors...
  85. ncbi Immunogenicity of therapeutic proteins. Part 1: impact of product handling
    Basant Sharma
    Pharmaceutical Technology, Global Biologics Supply Chain LLC, HTD 6 2, Horsham, PA 19044, USA
    Biotechnol Adv 25:310-7. 2007
    ....
  86. ncbi Using computerized data to identify adverse drug events in outpatients
    B Honigman
    University of Colorado Health Sciences Center, Denver, USA
    J Am Med Inform Assoc 8:254-66. 2001
    ....
  87. ncbi Sex differences in drug metabolism: cytochrome P-450 and uridine diphosphate glucuronosyltransferase
    Gail D Anderson
    Department of Pharmacy, Box 357630, University of Washington, Seattle, WA 98195, USA
    J Gend Specif Med 5:25-33. 2002
    ..However, genetics also controls the amount (or activity) of the enzymes. Sex-dependent differences have been demonstrated for several CYP isoenzymes and for UGT. Ethnicity also appears to play a role in the activity of these enzymes...
  88. ncbi Hormonal regulation of hepatic drug-metabolizing enzyme activity during adolescence
    Mj Kennedy
    Kosair Charities Pediatric Clinical Research Unit, Department of Pediatrics, School of Medicine, University of Louisville, Louisville, Kentucky, USA
    Clin Pharmacol Ther 84:662-73. 2008
    ....
  89. ncbi Quality assessment of internet pharmaceutical products using traditional and non-traditional analytical techniques
    Benjamin J Westenberger
    Food and Drug Administration, Division of Pharmaceutical Analysis, 1114 Market Street, St Louis, MO 63101, USA
    Int J Pharm 306:56-70. 2005
    ..For example, these methods detected suspect manufacturing issues (such as blending), which were not evident from traditional testing alone...
  90. ncbi Influence of drugs and comorbidity on serum potassium in 15 000 consecutive hospital admissions
    Samuel Henz
    Department of Internal Medicine, Kantonsspital, CH 9007 St Gallen, Switzerland
    Nephrol Dial Transplant 23:3939-45. 2008
    ..Nevertheless, after approval, these drugs will be prescribed to a much broader collective. Our goal was to quantify the impact of drugs and comorbidity on serum potassium in unselected patients admitted to the hospital...
  91. ncbi Prediction of P-glycoprotein substrates by a support vector machine approach
    Y Xue
    Department of Computational Science, National University of Singapore, Blk SOC1, Level 7, 3 Science Drive 2, Singapore 117543
    J Chem Inf Comput Sci 44:1497-505. 2004
    ..5 decision tree, that use the same sets of data and molecular descriptors. Our study indicates the potential of SVM in facilitating the prediction of P-gp substrates...
  92. ncbi Predicting drug-drug interactions: an FDA perspective
    Lei Zhang
    Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Rm 3188, Bldg 51, 10903 New Hampshire Avenue, Silver Spring, Maryland 20993, USA
    AAPS J 11:300-6. 2009
    ..This report summarizes critical elements in the in vitro evaluation of drug interaction potential during drug development and uses a case study to highlight the impact of in vitro information on drug labeling...
  93. ncbi The properties of known drugs. 1. Molecular frameworks
    G W Bemis
    Vertex Pharmaceuticals, Cambridge, Massachusetts 02139 4242, USA
    J Med Chem 39:2887-93. 1996
    ..We discuss the possible interpretations of these findings and the way they may be used to guide future drug discovery research...
  94. ncbi SuperPred: drug classification and target prediction
    Mathias Dunkel
    Institute of Molecular Biology and Bioinformatics, Charite University Medicine Berlin, Arnimallee 22, 14195 Berlin, Germany
    Nucleic Acids Res 36:W55-9. 2008
    ..Availability: the system is freely accessible at http://bioinformatics.charite.de/superpred. SuperPred can be obtained via a Creative Commons Attribution Noncommercial-Share Alike 3.0 License...
  95. ncbi Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands
    Anne J Leendertse
    Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht University, Utrecht, The Netherlands
    Arch Intern Med 168:1890-6. 2008
    ..Furthermore, little information exists on potential risk factors associated with preventable medication-related hospitalizations...
  96. ncbi Investigating drug-induced mitochondrial toxicity: a biosensor to increase drug safety?
    Cláudia V Pereira
    Center for Neurosciences and Cell Biology, Department of Zoology, University of Coimbra, Coimbra, Portugal
    Curr Drug Saf 4:34-54. 2009
    ....
  97. ncbi Large-scale production of pharmaceuticals by marine sponges: sea, cell, or synthesis?
    Detmer Sipkema
    Food and Bioprocess Engineering Group, Wageningen University, P O Box 8129, 6700 EV Wageningen, The Netherlands
    Biotechnol Bioeng 90:201-22. 2005
    ..It was concluded that the latter two approaches could prove to be valuable methods for the production of pharmaceuticals, based on chemical structures of secondary metabolites present in trace amounts in marine sponges...
  98. ncbi A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs
    Christine Lonjou
    INSERM, U563 Paul Sabatier University III, Toulouse, France
    Pharmacogenet Genomics 18:99-107. 2008
    ..Recently, a strong association between carbamazepine and allopurinol induced SJS or TEN has been described with respectively, HLA-B*1502 and HLA-B*5801 in a Han Chinese population from Taiwan and other Asian countries...
  99. ncbi Enhancing the effectiveness of virtual screening by fusing nearest neighbor lists: a comparison of similarity coefficients
    Martin Whittle
    Krebs Institute for Biomolecular Research and Department of Information Studies, University of Sheffield, Western Bank, Sheffield S10 2TN, U K
    J Chem Inf Comput Sci 44:1840-8. 2004
    ..The use of group recall can lead to improved enrichment in database searches and virtual screening...
  100. ncbi Random forest models to predict aqueous solubility
    David S Palmer
    Unilever Centre for Molecular Science Informatics, Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK
    J Chem Inf Model 47:150-8. 2007
    ..Finally, the diversity of the training and test sets are compared to the chemical space occupied by molecules in the MDL drug data report, on the basis of molecular descriptors selected by the regression analysis...
  101. ncbi Nanostructured bacterial materials for innovative medicines
    Escarlata Rodríguez-Carmona
    Institute for Biotechnology and Biomedicine, Universitat Autonoma de Barcelona, Bellaterra, Barcelona, Spain
    Trends Microbiol 18:423-30. 2010
    ....

Research Grants142 found, 100 shown here

  1. Mechanisms of Manganese Neurotoxicity
    ANUMANTHA GOUNDER KANTHASAMY; Fiscal Year: 2010
    ..problem resulting from the use of Mn as a gasoline additive, and its use in welding rods, pesticides, pharmaceutical preparations, alloy manufacturing, and in dry cell battery production, for instance...
  2. Mechanisms of Manganese Neurotoxicity
    ANUMANTHA GOUNDER KANTHASAMY; Fiscal Year: 2010
    ..problem resulting from the use of Mn as a gasoline additive, and its use in welding rods, pesticides, pharmaceutical preparations, alloy manufacturing, and in dry cell battery production, for instance...
  3. TARGETED METAL CHELATORS FOR DIAGNOSTIC IMAGING
    Michael Welch; Fiscal Year: 2001
    ..The synthesis characterization and physicochemical studies will be carried out at Texas A&M University while the in vitro and in vivo evaluation of the pharmaceutical preparations will be undertaken at Washington University.
  4. TARGETED METAL CHELATORS FOR DIAGNOSTIC IMAGING
    Michael Welch; Fiscal Year: 1993
    ..and physicochemical studies will be carried out at Texas A&M University with non-radioactive isotopes while in vitro and in vivo evaluation of the pharmaceutical preparations will be carried out at Washington University.
  5. Bi(III)-Initiated Chemistry: Mechanistic Investigations of Catalytic Activity
    Robert Hinkle; Fiscal Year: 2007
    ..In fact, bismuth compounds have been widely utilized in pharmaceutical preparations for over 400 years...
  6. Label Free Pharmaceutical Anticounterfeiting Technology
    ROBERT HAUSHALTER; Fiscal Year: 2007
    ..However, an anticounterfeiting method to protect pharmaceutical preparations directly at the pill level presents a singularly stringent set of requirements in terms of employing a ..
  7. CONTROLLED RELEASE OF MACROMOLECULES
    Robert Langer; Fiscal Year: 2003
    ..The stabilization of DNA in viable long-term pharmaceutical preparations is one critical part toward the advance of gene therapy to the clinic...
  8. Pharmaceutical Anticounterfeiting Technology
    ROBERT HAUSHALTER; Fiscal Year: 2005
    ..has prevented any of these techniques from evolving into a widely used and effective system to protect pharmaceutical preparations. Parallel Synthesis Technologies proposes the use of an inexpensive and easy to use encoding technology,..
  9. ACYL GLUCURONIDES: COVALENT BINDING & PHARMACOKINETICS
    Leslie Benet; Fiscal Year: 1993
    ..investigate the relationship between irreversible binding in vivo and immunological toxicity...
  10. Metabolism of Carcinogens and Drugs by Human P450s
    F Guengerich; Fiscal Year: 2007
    ....
  11. ACYLCOA FORMATION--COVALENT BINDING, PHARMACOKINETICS
    Leslie Benet; Fiscal Year: 2002
    ....
  12. BIOACTIVATION OF HALOGENATED HYDROCARBONS
    F Guengerich; Fiscal Year: 2005
    ..These experiments involving enzymatic oxidation and conjugation reactions are intended to help define important concepts that can be applied to other halogenated hydrocarbons and to other cancer suspect chemicals as well. ..
  13. Novel Approaches to Blood Brain Barrier Function
    Alex Avdeef; Fiscal Year: 2007
    ....
  14. Polymerase Interactions with Carcinogen-modified DNA
    F Peter Guengerich; Fiscal Year: 2010
    ..The goals of this project involve understanding how the DNA polymerases make such mistakes. ..
  15. Physics-based Simulation of Biological Structures(RMI)
    Russ Altman; Fiscal Year: 2007
    ..It will thus provide a critical piece of a national biomedical computing infrastructure. ..
  16. Annotating functional sites in 3D biological structures
    RUSS BIAGIO ALTMAN; Fiscal Year: 2010
    ..In particular, we will focus our new capabilities on three difficult function annotation challenges: ATP binding sites, phosphorylation sites, and metabolizing enzyme active sites. ..
  17. Design and Characterization of DNA Interactive Agents
    Jennifer Brodbelt; Fiscal Year: 2005
    ..The anticancer and antibacterial effects of UK-1 and A-62176 analogs will be examined in a range of human cancer cell lines and Gram negative and Gram positive bacteria. ..
  18. POLYMERASE INTERACTIONS WITH CARCINOGEN MODIFIED DNA
    F Guengerich; Fiscal Year: 2004
    ..The overall goal is understanding molecular mechanisms of mutagenesis as a part of chemical carcinogenesis. ..
  19. Hyopthyroidism Treatment in Aging and Thyroid Cancer
    Offie P Soldin; Fiscal Year: 2010
    ..This will help in setting therapeutic goals and help millions in diagnosis, treatment and management of thyroid disease in aging. ..
  20. CHROMATOGRAPHIC STUDIES OF FUNCTIONAL PROTEOMICS
    DAVID HAGE; Fiscal Year: 2007
    ..This, in turn, should allow an improved description of how the transport, metabolism, and effective dose of a drug will differ between a diabetic patient and an individual without diabetes. ..
  21. CHROMATOGRAPHIC AUTOMATION OF IMMUNOASSAYS
    DAVID HAGE; Fiscal Year: 2004
    ..The result of this work should be the creation of new, more rapid tools for determining free drug or hormone levels, providing a better means for studying how such compounds behave and interact within our bodies. ..
  22. Analysis of Phenolic Phytochemical by ESI-MS
    Jennifer Brodbelt; Fiscal Year: 2003
    ....
  23. MECHANISMS OF TOXICITY GORDON CONFERENCE
    RONALD HINES; Fiscal Year: 2002
    ..There also is substantial involvement of new personnel as Chairs and co-Chairs. Thus, the Mechanism of Toxicity GRC is poised to continue its growth as the single leading small conference on Molecular Toxicology. ..
  24. Physiological functions of G-alpha-i/o and control by regulators of G protein sig
    Richard R Neubig; Fiscal Year: 2010
    ..By improving those therapeutically useful signals at the expense of signals leading to side effects, we can produce better medicines or can make existing medicines better tolerated. ..
  25. Design of Small Molecules Acting at Regulators of G Protein Signaling
    Richard R Neubig; Fiscal Year: 2010
    ..This project will provide the initial steps and proof of principle for medications development targeting RGS proteins - a key modulator of signaling related to drug abuse. ..
  26. Design of Small Molecules Acting at Regulators of G Protein Signaling
    Richard Neubig; Fiscal Year: 2007
    ..This project will provide the initial steps and proof of principle for medications development targeting RGS proteins - a key modulator of signaling related to drug abuse. ..
  27. Super-persistent cells and the paradox of untreatable infections
    Kim Lewis; Fiscal Year: 2009
    ..Our findings are likely to change the way we view infectious diseases and will provide rational approaches for discovering drugs that completely eradicate the infection. ..
  28. PEPTIDE MODULATORS OF G PROTEIN FUNCTION
    Richard Neubig; Fiscal Year: 2000
    ..The specificity of these "drugs" will be tested in cell culture with the aim of future use in gene therapy approaches to cardiovascular disease. ..
  29. PEPTIDE MODULATORS OF G PROTEIN FUNCTION
    Richard Neubig; Fiscal Year: 1993
    ....
  30. Biosensors for metabolic engineering
    Jay Keasling; Fiscal Year: 2006
    ..abstract_text> ..
  31. SCREEN DEVELOPMENT FOR ANTIMICROBIAL PRODRUGS
    Kim Lewis; Fiscal Year: 2007
    ....
  32. Contraceptive Services/Primary Care to Prevent Birth Defects
    Eleanor Schwarz; Fiscal Year: 2007
    ....